Carisma Therapeutics INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

OTC.Pink

26 Apr 2025

CARM

SCHEDULE 13G/A: AbbVie Biotechnology Reduces Stake in Carisma Therapeutics Below 5%

AbbVie Biotechnology Ltd. has filed an amended Schedule 13G, disclosing its beneficial ownership in Carisma Therapeutics Inc. has fallen to 4.4% of outstanding common stock.